Provided By GlobeNewswire
Last update: Nov 7, 2024
WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the third quarter of 2024.
Read more at globenewswire.comNASDAQ:AVTX (4/25/2025, 8:00:01 PM)
4.78
-0.1 (-2.05%)
Find more stocks in the Stock Screener